{"url_path":"/sec/cadl/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-222892-index.html","accession_number":"0001193125-26-222892","cik":"0001841387","ticker":"CADL","issuer_name":"Candel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-222892-index.html","primary_entity_key":"0001841387","primary_entity_name":"Candel Therapeutics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n 99.1\n\n[Press Release dated May 14, 2026](cadl-ex99_1.htm)\n\n 104\n\n Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCandel Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 14, 2026\n\nBy:\n\n/s/ Paul Peter Tak\n\n \n\n \n\n \n\nPaul Peter Tak, M.D., Ph.D., FMedSci\nPresident and Chief Executive Officer"}